Jazz Pharmaceuticals (JAZZ) Interest Expenses (2010 - 2013)

Jazz Pharmaceuticals' Interest Expenses history runs 17 years deep, the most recent figure standing at $578.5 million for Q1 2026.

• In Q1 2026, Interest Expenses fell 8.27% year-over-year to $578.5 million; the TTM figure through Mar 2026 stood at $578.5 million (down 8.27% YoY), while the FY2025 annual figure was $647.3 million, up 27.12% from the prior year.
• Interest Expenses for Q1 2026 stood at $578.5 million, up from $31.3 million in the prior quarter.
• The five-year high for Interest Expenses was $647.1 million in Q3 2024, with the low at $8.6 million in Q2 2024.
• The 5-year median for Interest Expenses is $602.4 million (2023), against an average of $470.0 million.
• The sharpest annual moves came in 2024 and 2025: Interest Expenses sank 98.61% in 2024, then soared 7398.91% in 2025.
• Jazz Pharmaceuticals' Interest Expenses stood at $25.2 million in 2022, then jumped by 1155.21% to $316.3 million in 2023, then fell by 1.2% to $312.5 million in 2024, then slumped by 89.98% to $31.3 million in 2025, then jumped by 1748.24% to $578.5 million in 2026.
• Business Quant data shows JAZZ's Interest Expenses at $578.5 million in Q1 2026, $31.3 million in Q4 2025, and $638.4 million in Q3 2025.